It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of malignant hyperthermia susceptibility.We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing malignant hyperthermia.We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings

Hopkins, P.M., Rüffert, H., Snoeck, M.M., Girard, T., Glahn, K.P.E., Ellis, F.R., et al. (2015). European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. BRITISH JOURNAL OF ANAESTHESIA, 115(4), 531-539 [10.1093/bja/aev225].

European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility

Sorrentino, V.;
2015-01-01

Abstract

It is 30 yr since the British Journal of Anaesthesia published the first consensus protocol for the laboratory diagnosis of malignant hyperthermia susceptibility from the European Malignant Hyperthermia Group. This has subsequently been used in more than 10 000 individuals worldwide to inform use of anaesthetic drugs in these patients with increased risk of developing malignant hyperthermia during general anaesthesia, representing an early and successful example of stratified medicine. In 2001, our group also published a guideline for the use of DNA-based screening of malignant hyperthermia susceptibility.We now present an updated and complete guideline for the diagnostic pathway for patients potentially at increased risk of developing malignant hyperthermia.We introduce the new guideline with a narrative commentary that describes its development, the changes to previously published protocols and guidelines, and new sections, including recommendations for patient referral criteria and clinical interpretation of laboratory findings
2015
Hopkins, P.M., Rüffert, H., Snoeck, M.M., Girard, T., Glahn, K.P.E., Ellis, F.R., et al. (2015). European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. BRITISH JOURNAL OF ANAESTHESIA, 115(4), 531-539 [10.1093/bja/aev225].
File in questo prodotto:
File Dimensione Formato  
Hopkins at al., 2015 BJP EMHG guidelines.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 205.66 kB
Formato Adobe PDF
205.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/980143